Dishman dumps project to raise cash; Bedford recalls more products; Goldman invests in Orchid;

> Beleaguered Bedford Laboratories issued recall of a lot of Vecuronium Bromide after its was discovered some vials contain particulates. FDA announcement

> Goldman Sachs has acquired about a 1% stake in API maker Orchid Chemicals, paying Rs86m ($1.51 million) for 742,001 shares. Item

> With the results of an arrhythmia safety study in, the FDA is having GlaxoSmithKline ($GSK) expand the labeling changes on its Zofran, which is used in chemotherapy for vomiting and nausea. Story

> Ampio Pharmaceuticals, has contracted with Syngene in Bangalore, India, to begin manufacturing the products it now has in clinical trials. Release

> Survey finds increase in single-use technology for fill and finish. Story

> Standard Process is recalling its dietary supplements Cataplex ACP, Cataplex C and Pancreatrophin PMG, which are generally provided through doctors, after a routine inspection by the FDA discovered one of the ingredients in them may be contaminated with salmonella. FDA alert

And Finally... Dishman Pharmaceuticals is dumping its 6-year-old Special Economic Zone project near Ahmedabad, India, and will sell the land and use the proceeds to pay off debt. Story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.